Hydra Biosciences, Inc Company Profile

05:22 EDT 23rd March 2018 | BioPortfolio

Hydra Biosciences is a biopharmaceutical company developing molecular regeneration medicines, novel cardiovascular therapies and drugs targeting novel ion channels. Tapping the unharnessed power of the body to heal itself is one of the last frontiers of medicine. With the identification of many animal genomes, it is now possible to identify the genes and pathways that can unleash the regenerative power locked within the human body.


790 Memorial Drive
United States of America


Phone: (617) 494 - 5230
Fax: (617) 494 - 5245

News Articles [533 Associated News Articles listed on BioPortfolio]

TRPC4/5 Inhibitor Now Investigated in Clinic for Central Nervous System Disorders

Collaboration between Hydra Biosciences and Boehringer Ingelheim initiated in 2014 now enters into clinical stage TRPC4/5 inhibitor is believed to provid...

ASC Biosciences, Inc. announces ad dates for first television commercial

About ASC Biosciences, Inc.ASC Biosciences, Inc. ("ASC" or the "Company") is a development stage biotechnology company with a proprietary adult stem cell platform capable Read more...

Kuros Biosciences Ltd.: Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus

Schlieren (Zürich), Schweiz, 8. Januar 2018 Kuros Biosciences weitet Lizenzabkommen mit Checkmate aus Kuros Biosciences AG (SIX: KURN) gibt die Ausdehnung des exklusiven Lizenzabkommens mit Checkm...

TRPC4/5 Inhibitor Now Investigated in Clinic for CNS Disorders

NewsNovel TRP ion channel modulators have the potential to meet both of these demands.Contributed Author: 

Apricus Biosciences, Inc.: Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros

Company Evaluating Deficiencies and Potential Path Forward SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative me...

Kuros Biosciences Ltd.: Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen

Schlieren (Zürich), Schweiz, 22. November 2017 Kuros Biosciences sichert mögliche Eigenkapitalfinanzierung von bis zu CHF 30 Millionen Kuros Biosciences (SIX: KURN) gibt den Abschluss eines Standb.....

Hydra Biosciences Inc Pharmaceuticals Healthcare Deals and Alliances Profile [Report Updated: 12032018] Prices from USD $250

SummaryHydra Biosciences Inc Hydra is a biopharmaceutical company that develops novel drugs. The company's pipeline candidate HX100 is developed to treat diabetic neuropathy and allergic asthma. It of...

Kuros Biosciences Ltd.: Kuros Biosciences gibt Nachfolge im Management bekannt

Schlieren (Zürich), Schweiz, 14. Dezember 2017 Kuros Biosciences gibt Nachfolge im Management bekannt Kuros Biosciences AG (SIX: KURN) gibt die Ernennung von Michael Grau zum Chief Financial Offic...

PubMed Articles [76 Associated PubMed Articles listed on BioPortfolio]

The effects of microplastic on freshwater Hydra attenuata feeding, morphology & reproduction.

Microplastic pollution has been a growing concern in the aquatic environment for several years. The abundance of microplastics in the environment has invariably led them to interact with a variety of ...

Physical Mechanisms Driving Cell Sorting in Hydra.

Cell sorting, whereby a heterogeneous cell mixture organizes into distinct tissues, is a fundamental patterning process in development. Hydra is a powerful model system for carrying out studies of cel...

Mitochondrial targeted doxorubicin-triphenylphosphonium delivered by hyaluronic acid modified and pH responsive nano-carriers to breast tumor: in vitro and in vivo studies.

Multidrug resistance (MDR) is the major obstacle for chemotherapy. In a previous study, we have successfully synthesized a novel doxorubicin (DOX) derivative modified by triphenylphosphonium (TPP) to ...

DNA repair enzyme APE1 from evolutionarily ancient Hydra reveals redox activity exclusively found in mammalian APE1.

Only mammalian apurinic/apyrimidinic endonuclease1 (APE1) has been reported to possess both DNA repair and redox activities. C terminal of the protein is required for base excision repair, while the r...

Sorting Things Out: Cell Sorting during Hydra Regeneration.

Clinical Trials [10 Associated Clinical Trials listed on BioPortfolio]

A Clinical Evaluation of the HYDRA Self Expanding Transcatheter Aortic Valve

The purpose of this study is the evaluation of the performance, safety and efficacy of Hydra Aortic valve in real-world patients. Following initial implantation, all patients will have cli...

Tangible Hydra-PEG: A Promising Solution for Scleral Lens Wearers With Dry Eye

Tangible Hydra-PEG is a novel coating technology designed to improve lens wettability, deposit resistance, and tear film breakup time. This is a randomized double masked cross-over study t...

Symptom Response in Normal and Dry Eye Patients Secondary to Application of a Menthol-Containing Eyedrop (Rohto® Hydra)

The purpose of the study is to analyze the sensation to eye drops containing menthol in people with healthy eyes and in people with dry eyes. This study also examines the temperature of yo...

HepaStem Long-Term Safety Registry

All patients having received at least one infusion of the Investigational Medicinal Product (IMP) HepaStem HHALPC during a previous interventional clinical study conducted by Promethera Bi...

Treatment of Alveolar Bone Defects Using Aastrom Biosciences Autologous Tissue Repair Cell Therapy

The purpose of this research is to determine if a subject's own bone marrow tissue can help regenerate bone in the area of his/her jaw where a tooth has been removed using Tissue Repair Ce...

Companies [346 Associated Companies listed on BioPortfolio]

Hydra Biosciences, Inc.

Hydra Biosciences is a privately-held biopharmaceutical company based in Cambridge, Massachusetts, and develops drugs to treat pain, inflammation, anxiety and other diseases using...

Hydra Biosciences, Inc

Hydra Biosciences is a biopharmaceutical company developing molecular regeneration medicines, novel cardiovascular therapies and drugs targeting novel ion channels. Tapping the unharnessed power of th...

Leadiant Biosciences, Inc.

Leadiant Biosciences, Inc. (formerly Sigma-Tau Pharmaceuticals, Inc.) is a U.S.-based, wholly owned subsidiary of Leadiant Biosciences S.p.A., a research-based pharmaceutical comp...

JeNu Biosciences

JeNu Biosciences was founded in 2008 by a team of ultrasound scientists, medical doctors and beauty executives and is currently led by Wayne Wager, CEO. JeNu Biosciences is a Seat...

DaVinci Biosciences LLC

DaVinci Biosciences LLC is a privately held company dedicated to advancing therapies that improve the quality of life for individuals suffering from trauma, disease and degenerative disorders. Through...

More Information about "Hydra Biosciences, Inc" on BioPortfolio

We have published hundreds of Hydra Biosciences, Inc news stories on BioPortfolio along with dozens of Hydra Biosciences, Inc Clinical Trials and PubMed Articles about Hydra Biosciences, Inc for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Hydra Biosciences, Inc Companies in our database. You can also find out about relevant Hydra Biosciences, Inc Drugs and Medications on this site too.

Quick Search


Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...

Corporate Database Quicklinks

Searches Linking to this Company Record